Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.
Beam Therapeutics was founded about a year ago to assemble the technology needed for scientists to edit DNA by changing a single letter in the genetic code, and now the company says it has the tools necessary to develop novel therapeutics.
Cambridge, Mass.-based Beam officially launched on May 14, revealing that the first-of-its-kind company has raised $87m in venture capital in...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
